Do biosimilars improve access to oncology medicines in Asia?
Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access
Some practice-changing results in breast cancer are perceived differently in low-resourced countries
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
Healthcare budgets are still a main hurdle to global use of molecular testing for precision oncology
Inequities in access to targeted cancer treatments are due to the high costs of tests, limited number of approved medicines or clinical trials and poor communication with patients, as two new surveys report
Trials in precision oncology: current snapshot and future innovations
Increased use of molecular profiling is progressively improving decision-making processes in oncology compared with 20 years ago and helping to shape tomorrow’s clinical trials in targeted therapies
Liquid biopsy: novel approaches for early detection of cancer
Multi-omics approaches incorporating cell-free DNA and circulating tumour DNA show potential in early cancer detection and could help personalise treatment by tumour characteristics
Novel liquid biomarkers show promise in predicting clinical outcomes with immunotherapy
Although encouraging results are presented, standardisation of methodology and large-scale clinical trials are needed before potential candidates can be used in routine clinical practice
Precision oncology is the goal today, not a simple slogan
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
The right to be forgotten reduces financial toxicity in cancer survivors
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
Breast cancer treatment should be tailored to the tumour biology – not to its hormone-receptor status alone
New insights into breast cancer immunology and genomics support further segmentation of patient subgroups and treatment approaches, says Prof. Sherene Loi
Closing the clinician–patient gap with patient-reported outcomes
PROs encourage patient-centred cancer care